Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.
JP DeVincenzo, MW McClure, JA Symons, H Fathi, C Westland, S Chanda, R Lambkin-Williams, P Smith, Q Zhang,L Beigelman,LM. Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks. 2017 Jul 83(7):1580-1594.ĪM Wollacott, MF Boni, KJ Szretter, SE Sloan, M Yousofshahi, K Viswanathan, S Bedard, CA Hay, PF Smith, Z Shriver, JM Trevejo. Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics. Kamal MA, Smith PF, Chaiyakunapruk N, Wu DBC, Pratoomsoot C, Lee KKC, Chong HY, Nelson RE, Nieforth K, Dall G, Toovey S, Kong DCM, Kamauu A, Kirkpatrick CM, Rayner CR. The Journal of antimicrobial chemotherapy, 74(2), 442–452. J Need help with mm, cm, m, and km conversions Youre in the right placeWhether youre just star.
Winnonlin 1 cm mm how to#
Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans. Welcome to how to Convert Metric Units of Length with Mr. A., Chanda, S., Zhang, Q., McClure, M., Fry, J., Symons, J. Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study. M., Smith, P., Skurnik, D., Bedard, S., Trevejo, J.
CPT: pharmacometrics & systems pharmacology, 10.1002/psp4.12543. Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load. Gonçalves, A., Bertrand, J., Ke, R., Comets, E., de Lamballerie, X., Malvy, D., Pizzorno, A., Terrier, O., Rosa Calatrava, M., Mentré, F., Smith, P., Perelson, A. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders. Rayner CR, Smith PF, Hershberger K, Wesche D. Dosing will be a key success factor in repurposing antivirals for COVID-19. Smith PF, Dodds M, Bentley D, Yeo K, Rayner C. Patrick has over 125 peer reviewed publications, in journals including NEJM and Lancet. With over 20 years of global drug development experience, Patrick works across all phases of development with particular expertise in infectious diseases, oncology, and inflammation as well as novel early development program design and applying modeling and simulation to solve critical development problems.